Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Salarius Pharmaceuticals Inc 2450 Holcombe Blvd. Suite X Houston TX 77021 USA

www.salariuspharma.com P: 832-834-9144

Description:

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals Inc., formerly known as Flex Pharma Inc., is based in Houston, Texas.

Key Statistics

Overview:

Market Capitalization, $K 2,426
Enterprise Value, $K -3,474
Shares Outstanding, K 4,776
Annual Sales, $ 0 K
Annual Net Income, $ -12,540 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -880 K
EBIT, $ -12,890 K
EBITDA, $ -12,880 K
60-Month Beta 1.01
% of Insider Shareholders 5.50%
% of Institutional Shareholders 11.88%
Float, K 4,514
% Float 94.50%
Short Volume Ratio 0.79

Growth:

1-Year Return -69.57%
3-Year Return -98.44%
5-Year Return -99.83%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 99.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.22 on 03/22/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -4.53
EPS Growth vs. Prev Qtr 66.15%
EPS Growth vs. Prev Year 92.23%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 10/17/22

SLRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -197.96%
Return-on-Assets % -135.23%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.38
Book Value/Share 1.34
Interest Coverage -1.19
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar